5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The latest report 5-Hydroxytryptamine Receptor 2B - Pipeline Review, H1 2017, outlays comprehensive information on the 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) - 5-Hydroxytryptamine receptor 2B (5-HT2B) or serotonin receptor 2B is a protein encoded by the HTR2B gene. It plays a role in the regulation of behavior, including impulsive behavior. It protects cardiomyocytes against apoptosis. It plays a role in the adaptation of pulmonary arteries to chronic hypoxia and vasoconstriction. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 2 and 5 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
To Get Request Sample report visit @ https://www.reportsmonitor.com/request-sample/?post=217667
Report covers products from therapy areas Central Nervous System, Cardiovascular, Gastrointestinal, Immunology, Respiratory, Metabolic Disorders, Oncology and Ophthalmology which include indications Drug Addiction, Attention Deficit Hyperactivity Disorder (ADHD), Irritable Bowel Syndrome, Migraine, Psychiatric Disorders, Psychosis, Pulmonary Arterial Hypertension, Schizophrenia, Systemic Sclerosis (Scleroderma), Abdominal Pain, Alzheimer's Disease, Bipolar Disorder (Manic Depression), Chronic Obstructive Pulmonary Disease (COPD), Cirrhosis, Hypertension, Idiopathic Pulmonary Fibrosis, Insomnia, Liver Fibrosis, Major Depressive Disorder, Memory Impairment, Neuroendocrine Tumors, Obesity, Ocular Hypertension, Open-Angle Glaucoma, Pervasive Developmental Disorder (PDD), Schizoaffective Disorder and Tourette Syndrome.
Furthermore, this report also reviews key players involved in 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
- The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B)
- The report reviews 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics and enlists all their major and minor projects
- The report assesses 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to 5-Hydroxytryptamine Receptor 2B (5 HT2B or Serotonin Receptor 2B or HTR2B) targeted therapeutics
To Browse Complete report visit @ https://www.reportsmonitor.com/5-hydroxytryptamine-receptor-2b-5-ht2b-or-serotonin-receptor-2b-or-htr2b-pipeline-review-h1-2017/
About Us
Reports Monitor (ReportsMonitor.com) is a platform for companies looking to meet their market research and business intelligence requirements. Our aim is to change the dynamics of the Market Research industry by providing quality intelligence backed by data. Your requirement for market forecasting is fulfilled by our exclusive quantitative and analytics driven intelligence. We have a vast collection of reports, covering maximum industries worldwide. Our process is meticulously planned and executed in order to use maximum resources and explore the market for getting genuine insights. The prime focus is to get reliable data, Decision makers can now rely on our distinct data gathering methods to get factual market forecasting and detailed analysis.
Contact Us
Jay Matthews
Direct: +1 513 549-5911
Email: [email protected]
Website: http://www.reportsmonitor.com